Company intelligence / Profile preview

Twinstrand Therapeutics

Winnipeg, Manitoba, Canadatwinstrandbio.com ↗

Ownership: Private
Development stage: Commercial

Overview

Twinstrand's lead drug, TST10088, was in Phase I clinical trials at the time of acquisition. The company's approach used modified versions of the plant toxin ricin as targeted prodrugs that are activated only within diseased cells, sparing healthy tissue. They also began developing antibody-based anti-toxin therapeutics for biodefense. No further clinical results are available post-acquisition.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Modified protein toxins (ricin-based prodrugs)Antibody-based therapeutics
Industry: Biotech

Partnerships

Cangene Corporation had previously partnered with Twinstrand on anti-toxin technology before acquiring the company outright.

Beyond the preview

Go deeper on Twinstrand Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Twinstrand Therapeutics.